Targeting Effector Memory T Cells with the Small Molecule Kv1.3 Blocker PAP-1 Suppresses Allergic Contact Dermatitis

Overview

Journal J Invest Dermatol

Publisher Elsevier

Specialty Dermatology

Date 2007 Feb 3

PMID 17273162

Citations 52

Authors

Philippe Azam

Ananthakrishnan Sankaranarayanan

Daniel Homerick

Stephen Griffey

Heike Wulff

Affiliations

Soon will be listed here.

Abstract

The voltage-gated potassium channel Kv1.3 has been recently identified as a molecular target that allows for selective pharmacological suppression of effector memory T (T(EM)) cells without affecting the function of naïve and central memory T cells. We here investigated whether PAP-1, a small molecule Kv1.3 blocker (EC50=2 nM), could suppress allergic contact dermatitis (ACD). In a rat model of ACD, we first confirmed that the infiltrating cells in the elicitation phase are indeed CD8+ CD45RC- memory T cells with high Kv1.3 expression. In accordance with its selective effect on T(EM) cells, PAP-1 did not impair sensitization, but potently suppressed oxazolone-induced inflammation by inhibiting the infiltration of CD8+ T cells and reducing the production of the inflammatory cytokines IFN-gamma, IL-2, and IL-17 when administered intraperitoneally or orally during the elicitation phase. PAP-1 was equally effective when applied topically, demonstrating that it effectively penetrates skin. We further show that PAP-1 is not a sensitizer or an irritant and exhibits no toxicity in a 28-day toxicity study. Based on these results we propose that PAP-1 could potentially be developed into a drug for the topical treatment of inflammatory skin diseases such as psoriasis.

Citing Articles

Unveiling new genetic insights in rheumatoid arthritis for drug discovery through Taxonomy3 analysis.

Kozlowska J, Humphryes-Kirilov N, Pavlovets A, Connolly M, Kuncheva Z, Horner J Sci Rep. 2024; 14(1):14153.

PMID: 38898196 PMC: 11186831. DOI: 10.1038/s41598-024-64970-0.

Pathophysiological Roles of Ion Channels in Epidermal Cells, Immune Cells, and Sensory Neurons in Psoriasis.

Kim H, Choi M, Jeon S, Jang Y, Yang Y Int J Mol Sci. 2024; 25(5).

PMID: 38474002 PMC: 10932231. DOI: 10.3390/ijms25052756.

Structures of the T cell potassium channel Kv1.3 with immunoglobulin modulators.

Selvakumar P, Fernandez-Marino A, Khanra N, He C, Paquette A, Wang B Nat Commun. 2022; 13(1):3854.

PMID: 35788586 PMC: 9253088. DOI: 10.1038/s41467-022-31285-5.

IL-17 Inhibits Oligodendrocyte Progenitor Cell Proliferation and Differentiation by Increasing K Channel Kv1.3.

Liu H, Yang X, Yang J, Yuan Y, Wang Y, Zhang R Front Cell Neurosci. 2021; 15:679413.

PMID: 34239419 PMC: 8258110. DOI: 10.3389/fncel.2021.679413.

Insight into the mechanism of cytotoxicity of membrane-permeant psoralenic Kv1.3 channel inhibitors by chemical dissection of a novel member of the family.

Peruzzo R, Mattarei A, Azzolini M, Becker-Flegler K, Romio M, Rigoni G Redox Biol. 2020; 37:101705.

PMID: 33007503 PMC: 7527709. DOI: 10.1016/j.redox.2020.101705.

References

Krueger G . Selective targeting of T cell subsets: focus on alefacept - a remittive therapy for psoriasis. Expert Opin Biol Ther. 2002; 2(4):431-41. DOI: 10.1517/14712598.2.4.431. View

Suda A, Yamashita M, Tabei M, Taguchi K, Vohr H, Tsutsui N . Local lymph node assay with non-radioisotope alternative endpoints. J Toxicol Sci. 2002; 27(3):205-18. DOI: 10.2131/jts.27.205. View

Nakae S, Komiyama Y, Nambu A, Sudo K, Iwase M, Homma I . Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity. 2002; 17(3):375-87. DOI: 10.1016/s1074-7613(02)00391-6. View

Liu Q, Fleischmann B, Hondowicz B, Maier C, Turka L, Yui K . Modulation of Kv channel expression and function by TCR and costimulatory signals during peripheral CD4(+) lymphocyte differentiation. J Exp Med. 2002; 196(7):897-909. PMC: 2194034. DOI: 10.1084/jem.20020381. View

Kraan M, van Kuijk A, Dinant H, Goedkoop A, Smeets T, de Rie M . Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum. 2002; 46(10):2776-84. DOI: 10.1002/art.10543. View

Rappersberger K, Komar M, Ebelin M, Scott G, Burtin P, Greig G . Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated. J Invest Dermatol. 2002; 119(4):876-87. DOI: 10.1046/j.1523-1747.2002.00694.x. View

Krueger G, Papp K, Stough D, Loven K, Gulliver W, Ellis C . A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol. 2002; 47(6):821-33. DOI: 10.1067/mjd.2002.127247. View

Dearman R, Betts C, Humphreys N, Flanagan B, Gilmour N, Basketter D . Chemical allergy: considerations for the practical application of cytokine profiling. Toxicol Sci. 2003; 71(2):137-45. DOI: 10.1093/toxsci/71.2.137. View

Yoshida Y, Sakaguchi H, Ito Y, Okuda M, Suzuki H . Evaluation of the skin sensitization potential of chemicals using expression of co-stimulatory molecules, CD54 and CD86, on the naive THP-1 cell line. Toxicol In Vitro. 2003; 17(2):221-8. DOI: 10.1016/s0887-2333(03)00006-7. View

10.

Wulff H, Calabresi P, Allie R, Yun S, Pennington M, Beeton C . The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS. J Clin Invest. 2003; 111(11):1703-13. PMC: 156104. DOI: 10.1172/JCI16921. View

11.

Meingassner J, Fahrngruber H, Bavandi A . Pimecrolimus inhibits the elicitation phase but does not suppress the sensitization phase in murine contact hypersensitivity, in contrast to tacrolimus and cyclosporine A. J Invest Dermatol. 2003; 121(1):77-80. DOI: 10.1046/j.1523-1747.2003.12331.x. View

12.

Gupta A, Chow M . Pimecrolimus: a review. J Eur Acad Dermatol Venereol. 2003; 17(5):493-503. DOI: 10.1046/j.1468-3083.2003.00692.x. View

13.

Mackenzie A, Chirakkal H, North R . Kv1.3 potassium channels in human alveolar macrophages. Am J Physiol Lung Cell Mol Physiol. 2003; 285(4):L862-8. DOI: 10.1152/ajplung.00095.2003. View

14.

Wulff H, Beeton C, Chandy K . Potassium channels as therapeutic targets for autoimmune disorders. Curr Opin Drug Discov Devel. 2003; 6(5):640-7. View

15.

Vicente R, Escalada A, Coma M, Fuster G, Sanchez-Tillo E, Lopez-Iglesias C . Differential voltage-dependent K+ channel responses during proliferation and activation in macrophages. J Biol Chem. 2003; 278(47):46307-20. DOI: 10.1074/jbc.M304388200. View

16.

Gutman G, Chandy K, Adelman J, Aiyar J, Bayliss D, Clapham D . International Union of Pharmacology. XLI. Compendium of voltage-gated ion channels: potassium channels. Pharmacol Rev. 2003; 55(4):583-6. DOI: 10.1124/pr.55.4.9. View

17.

Goedkoop A, de Rie M, Picavet D, Kraan M, Dinant H, van Kuijk A . Alefacept therapy reduces the effector T-cell population in lesional psoriatic epidermis. Arch Dermatol Res. 2004; 295(11):465-73. DOI: 10.1007/s00403-004-0450-y. View

18.

Chandy K, Wulff H, Beeton C, Pennington M, Gutman G, Cahalan M . K+ channels as targets for specific immunomodulation. Trends Pharmacol Sci. 2004; 25(5):280-9. PMC: 2749963. DOI: 10.1016/j.tips.2004.03.010. View

19.

Vissers W, Arndtz C, Muys L, van Erp P, de Jong E, van de Kerkhof P . Memory effector (CD45RO+) and cytotoxic (CD8+) T cells appear early in the margin zone of spreading psoriatic lesions in contrast to cells expressing natural killer receptors, which appear late. Br J Dermatol. 2004; 150(5):852-9. DOI: 10.1111/j.1365-2133.2004.05863.x. View

20.

Fasth A, Cao D, Vollenhoven R, Trollmo C, Malmstrom V . CD28nullCD4+ T cells--characterization of an effector memory T-cell population in patients with rheumatoid arthritis. Scand J Immunol. 2004; 60(1-2):199-208. DOI: 10.1111/j.0300-9475.2004.01464.x. View